Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis

Simple item page
dc.contributor.authoral-Badri, Marwa R.
dc.contributor.authorAzar, Sami T.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:42:53Z
dc.date.available2025-01-24T11:42:53Z
dc.date.issued2014
dc.description.abstractGlucagon-like peptide-1 (GLP-1) agonists are a class of drugs used for the treatment of type 2 diabetes mellitus. GLP-1 is released in response to meal intake; these classes of drugs enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic effects following their release into the circulation from the gut. Psoriasis is a chronic skin condition affecting approximately 2% of the Western population. It is considered to be an autoimmune disease that involves the Th1 pathway and is associated with metabolic syndrome and its components, such as obesity, diabetes, and hypertension. We have reviewed reports in the literature that indicate a beneficial anti-inflammatory effect of GLP-1 in patients with diabetes or who have insulin resistance and psoriasis. © 2014, SAGE Publications. All rights reserved.
dc.identifier.doihttps://doi.org/10.1177/2042018814543483
dc.identifier.eid2-s2.0-84906350421
dc.identifier.urihttp://hdl.handle.net/10938/30123
dc.language.isoen
dc.relation.ispartofTherapeutic Advances in Endocrinology and Metabolism
dc.sourceScopus
dc.subjectDipeptidyl peptidase-4 inhibitors
dc.subjectGlucagon-like peptide-1
dc.subjectGlycemic control
dc.subjectIncretin
dc.subjectLiraglutide
dc.subjectMetabolic syndrome
dc.subjectObesity
dc.subjectPsoriasis
dc.subjectType 2 diabetes
dc.subjectAdalimumab
dc.subjectDipeptidyl peptidase iv
dc.subjectEtretin
dc.subjectExendin 4
dc.subjectGlucagon like peptide 1 receptor
dc.subjectGlucagon like peptide 1 receptor agonist
dc.subjectImmunoglobulin enhancer binding protein
dc.subjectInterleukin 17
dc.subjectInterleukin 7
dc.subjectPhosphatidylinositol 4, 5 bisphosphate 3 kinase
dc.subjectSitagliptin
dc.subjectTumor necrosis factor alpha
dc.subjectUnclassified drug
dc.subjectAntiinflammatory activity
dc.subjectDiabetes mellitus
dc.subjectDisease severity
dc.subjectDrug effect
dc.subjectGamma delta t lymphocyte
dc.subjectHuman
dc.subjectInsulin resistance
dc.subjectNatural killer cell
dc.subjectNon insulin dependent diabetes mellitus
dc.subjectNonhuman
dc.subjectPriority journal
dc.subjectRandomized controlled trial (topic)
dc.subjectReview
dc.subjectSkin cell
dc.titleEffect of glucagon-like peptide-1 receptor agonists in patients with psoriasis
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2014-10704.pdf
Size:
775.7 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine